News | May 18, 2025
Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Gelhaus has a proven track record of driving business growth
The Q1 2025 also witnessed a successful launch of Allegra D
Bayer expects 2025 to be the most difficult year of its turnaround
A new weapon in the global fight against malaria
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
AstraZeneca Pharma India discontinues manufacturing of Imdur
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated
